RxDoctor Payments DataLook up a doctor →

Hanh Bui, MD

Cardiovascular Disease · Vista, CANPI 1275519175

Payments from drug & device makers

$2,710,546in general payments, 2019–2025

Across 738 payments — averaging $3672.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • Janssen Research & Development, LLC$713K
  • Merck$260K
  • Astrazeneca UK Limited$200K
  • Bayer$198K
  • AstraZeneca$157K
  • plus $142K from 42 others

What the payments were for

  • Consulting fees$11,32540%
  • Travel & lodging$3,63313%
  • Food & beverage$13,52147%
  • Education$1651%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710,546 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,296,275
Medicare patients
1,328
Services billed
15,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban716$802,817
EntrestoSacubitril/Valsartan272$312,923
OzempicSemaglutide221$266,449
JardianceEmpagliflozin161$134,190
XareltoRivaroxaban115$114,526
MounjaroTirzepatide55$60,847
Repatha SureclickEvolocumab41$45,661
TrulicityDulaglutide39$39,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$36,742
Repatha SyringeEvolocumab20$22,012
MultaqDronedarone Hcl16$22,009
FarxigaDapagliflozin Propanediol20$21,282
JanuviaSitagliptin Phosphate24$17,918
BrilintaTicagrelor29$17,279
VerquvoVericiguat18$12,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$554$802,817716 claims
NovartisEntresto$1,042,181$312,923272 claims
Novo NordiskOzempic$234$266,449221 claims
Boehringer IngelheimJardiance$15,468$134,190161 claims
Johnson & JohnsonXarelto$419$114,526115 claims
Lilly USA, LLCMounjaro, Trulicity$312$100,69394 claims
GSKTrelegy Ellipta, Anoro Ellipta$390$48,04150 claims
AstraZenecaFarxiga, Brilinta$156,671$38,56149 claims
MerckJanuvia, Verquvo$260,065$30,64842 claims
Sanofi-aventis U.S. LLCMultaq$300$22,00916 claims
Arbor Pharmaceuticals, Inc.Edarbi$28$5,89614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →